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EXECUTIVE SUMMARY
Depression is highly prevalent among people living with HIV in Malawi, as in other countries
across the globe. Depression can undermine ART adherence, retention in care, and, ultimately,
viral suppression. Identifying and treating depression may be key to improving engagement in
care across the HIV care continuum.
In Malawi, as in other sub-Saharan countries, mental health care infrastructure and resources
are limited. Accordingly, there is a clear need to shift the provision of mental health treatment
to the primary care level. The Malawi Ministry of Health, in partnership with UNC Project-Malawi,
designed a program that would integrate depression screening and management into HIV care
at two public HIV clinics in Lilongwe, Malawi. The purpose of this study, conducted under Project
SOAR, was to evaluate the implementation of this program and its impact on HIV and mental
health outcomes.

METHODOLOGY
The primary objective of this study was to evaluate the impact of a practical, evidence-based
mental health treatment program integrated with HIV care, feasible for scale-up within the Malawi
health system, on mental health and HIV treatment outcomes. The program focused on training
existing ART staff and providers to screen for depression and prescribe antidepressants and
training existing lay health workers as depression counselors.
The study employed a pre-post multiple baseline design in two public health clinics in urban
Lilongwe. All patients starting ART and identified as having mild, moderate, or severe depressive
symptoms (PHQ-9 score ≥5) during the screening phase were followed forward until six months
after ART initiation for HIV appointment attendance, viral load, and depressive symptom
outcomes. During the screening (“pre“) phase, depression screening was integrated into ART
initiation and providers were re-oriented to existing depression treatment options. During the
active (“post“) phase, providers were additionally trained in algorithm-guided antidepressant
prescription for moderate to severe depression, and lay health workers were trained in Friendship
Bench problem-solving therapy for mild depression.
Data were collected from clinical records on HIV appointment attendance, viral suppression, and
depressive symptoms during the first six months after ART initiation.

KEY FINDINGS
Feasibility of integrating depression screening
Depression screening proved highly feasible to integrate with ART initiation. Screening was
divided such that the initial 2-item PHQ-2 screen was completed with the HIV post-test counselor,
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and only those with a positive PHQ-2 score went on to complete the full PHQ-9 with their HIV
clinician. Overall, among 2,069 patients initiating ART during the study, 96 percent completed the
full depression screening process; only 4 percent either did not complete the PHQ-2, or scored
positive on the PHQ-2 and failed to complete the PHQ-9.

Characteristics of patients
Patient characteristics were comparable between the screening and active phases, supporting
the argument that the study design appropriately controlled for confounding. In both phases
slightly fewer than half of patients were male; the mean age was approximately 33.8 years;
virtually all patients were asymptomatic (WHO Stage I); approximately 25 percent of patients had
mild, moderate, or severe depressive severity; and approximately 5 percent of patients indicated
passive or active suicidal thoughts.

Feasibility of initiating depression treatment
Depression treatment initiation also proved feasible to integrate into ART care. Of the 156
patients identified with mild depression during the active phase, 87 percent initiated Friendship
Bench counseling. Of the 55 patients identified with moderate to severe depression, 96 percent
initiated an antidepressant.

Consistency of HIV appointment attendance
Loss to HIV care was high. Fully one-quarter of patients did not return for their first ART refill
appointment, and over half were out of care at six months. These results were comparable during
the screening and active phases.

Feasibility of sustaining depression treatment
Sustaining depression treatment proved challenging, in part because many patients missed
follow-up ART appointments or were quickly lost to care. Of the 140 patients who started the
Friendship Bench, 57 percent attended at least two sessions and 33 percent attended at least
four sessions out of the recommended six sessions. Although the Friendship Bench was originally
designed as a weekly program, most patients cited time or financial barriers to making extra trips
to the clinic and aligned follow-up counseling sessions with their monthly ART appointments. Of
the 55 patients who were initially prescribed an antidepressant, 31 percent received at least
three months of antidepressant prescriptions, while the remainder received only one or two
months of medication before discontinuing.

Program impact on HIV and depression outcomes
Our primary outcome was HIV treatment success at six months, stringently defined as never
more than two weeks late to a scheduled appointment in the first six months of care and a viral
load <1,000 copies/mL at approximately six months post-ART initiation. There was no evidence
of improved HIV treatment success in the active phase (18%) relative to the screening phase
(25%). Similarly, no difference between the phases was evident in a range of secondary outcomes
including being in care at six months, proportion of ART appointments attended within one week,
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consistent ART supply through six months, viral suppression at six months, and PHQ-9 depressive
symptom severity score at six months.

CONCLUSION AND RECOMMENDATIONS
The SOAR-Malawi Mental Health Project demonstrated that it is feasible to integrate universal
depression screening and evidence-based antidepressant management and problem-solving
therapy counseling into routine care using existing staff in low-resource ART clinics in Malawi.
Different challenges were raised by integration of antidepressants and counseling. After a 1-day
training, clinicians were comfortable initiating antidepressants and did so systematically with very
little increased time cost. However, because of challenging medical record systems, returning
patients on antidepressants were inconsistently identified and often did not have their depressive
symptom level re-assessed or receive a refill of their antidepressant. Occasional stockouts
also affected medication supply. Counseling, on the other hand, was not affected by stockouts
or medical record challenges. However, counseling was significantly more time-intensive, and
integration into the workload of existing staff proved infeasible. Further, follow-up for counseling
was poor, and few patients ended up receiving the recommended six sessions.
A large proportion of patients missed HIV appointments or stopped coming altogether in both
the screening and active phases. Among those who did remain in care, viral suppression
and depression remission at six months were both very high. We saw no evidence of greater
improvement in HIV care or mental health outcomes with the depression treatment program
relative to the screening phase. This may have been because most depression at ART initiation
was time-limited adjustment disorder, because even the basic one-time counseling provided
during the screening phase was impactful, or because ART initiation and subsequent physical
health improvement led to mental health improvement in both phases.
Several key recommendations arise from the SOAR-Malawi Mental Health Project.
First, efforts to integrate depression screening and treatment within routine ART care in resourcelimited settings are definitely feasible, but will greatly benefit from the following:
• A dedicated on-site champion with strong investment in program success either through
financial support, strong institutional commitment, or other strategies.
• Integration with electronic medical record systems where feasible (many clinics in Malawi use
the Baobab electronic system for ART records), which would ensure that screening is completed
and returning patients on antidepressant treatment are identified and re-assessed.
• Dedicated counseling personnel (other research has demonstrated that community members,
who may be willing to commit for a small stipend, can be trained and supervised to effectively
deliver problem-solving therapy).
• Identification of appropriate and sustainable incentives (monetary or non-monetary) that will
ensure that clinicians participate in clinical supervision sessions to maintain and enhance
these new skills.
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• Identification of appropriate and sustainable means of support to encourage patients to
complete the recommended weekly counseling sessions.
Second, this program did not find evidence that HIV care or mental health outcomes improved
during the treatment program relative to the screening phase. While this program focused on
patients newly initiating ART as a population at high risk for loss to care, depression treatment
may be more important for returning patients who may present with more persistent or severe
depressive symptoms and face challenges in maintaining long-term ART adherence and HIV care
engagement. Therefore, programs that seek to integrate mental health screening and treatment
into HIV primary care should not restrict themselves to new patients but should evaluate the
mental health needs of all patients.
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INTRODUCTION
Depression is highly prevalent among people living with HIV in Malawi as in other countries across
the globe. While research in Africa is limited, studies have found that depression affects 18 to
30 percent of people living with HIV (Nakimuli-Mpungu et al. 2011). In Malawi, the prevalence
of depression among people living with HIV varies between 1 and 19 percent (Dow et al. 2014;
Harrington et al. 2018; Kim et al. 2014; Malava et al. 2018). The high prevalence of depression
among this vulnerable group indicates a need for mental health screening and treatment.
Depression can undermine ART adherence, retention in care, and, ultimately, viral suppression.
Depression is a barrier to ART retention and is associated with reduced ART adherence and viral
suppression (Franke et al. 2013; Gonzalez et al. 2011; Kidia et al. 2015; Nakimuli-Mpungu et al.
2011; Pence et al. 2007; Smillie et al. 2014) as well as greater perceived stigma and faster HIV
clinical progression (Gonzalez et al. 2011; Ickovics et al. 2001; Leserman et al. 2007; Leserman
2008; Pence et al. 2007). Fortunately, some studies have shown that depression treatment may
improve ART adherence and other HIV outcomes (Gaynes et al. 2015; Sin and DiMatteo 2014;
Tsai et al. 2010; Walkup et al. 2008; Yun et al. 2005). Identifying and treating depression may be
key to improving engagement in care across the HIV care continuum.
In Malawi, as in other sub-Saharan African countries, there are significant barriers to mental
health care seeking and limited mental health care infrastructure and resources. Stigma, cultural
beliefs around mental illness, and lack of knowledge of mental health all negatively impact
access to mental health care services (Crabb et al. 2012; Udedi 2016). The country currently
treats mental healthcare as a specialized service, often only provided by mental health specialists
in specialized tertiary facilities. Furthermore, there are few such specialists and facilities; there
are only three psychiatrists and three functioning public psychiatric hospitals in the country
(Udedi et al. 2018). As it is unlikely that the number of specialized service providers and
infrastructure could grow rapidly enough to meet the demands of the population, there is a clear
need to shift the provision of mental health treatment to the primary care level.
Depression screening and management programs and tools for non-mental health specialists in
Africa exist. Validated screening tools for depression, such as the Patient Health Questionnaire-9,
are now available for the sub-Saharan region (Ali, Ryan, and De Silva 2016; Chorwe-Sungani and
Chipps 2017). Depression treatment programs using antidepressant and psychosocial therapies
have also been developed (Adams et al. 2012a; Adams et al. 2012b; Chibanda et al. 2011;
Chibanda et al. 2016; Gaynes et al. 2015; Pence et al. 2014; Wagner, Slaughter, and GhoshDastidar 2017). Notably, in Cameroon, a measurement-based care program successfully treated
depression among people living with HIV (Gaynes et al. 2015; Pence et al. 2014). In Zimbabwe,
a problem-solving therapy intervention delivered by lay health workers proved efficacious
in improving common mental disorders among patients in primary care in a large clusterrandomized trial (Chibanda et al. 2017; Chibanda et al. 2011; Chibanda et al. 2016). While
such programs have proven to be efficacious, they are infrequently adapted, implemented, and
evaluated in real-world programmatic contexts in the sub-Saharan region.
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The Malawi Ministry of Health (MOH) has committed to achieving the UNAIDS 90-90-90 goals,
calling for 90 percent of those HIV-infected to be aware of their status, 90 percent of those
aware of their status to be on sustained antiretroviral therapy (ART), and 90 percent of those on
ART to be virally suppressed (UNAIDS 2014). Simultaneously, the noncommunicable diseases
(NCDs) and Mental Health Unit of the Malawi MOH has prioritized the integration of mental health
services into other general health services and the development of mental health capacity of
general providers (Government of Malawi Ministry of Health 2013; Government of Malawi Ministry
of Health 2017; Lupafya et al. 2016). The MOH, in partnership with UNC-Project Malawi, designed
a program that would integrate depression screening and management into HIV care at two public
HIV clinics in Lilongwe, Malawi. The purpose of this study, conducted under Project SOAR, was to
evaluate the implementation of this program and its impact on HIV and mental health outcomes.
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METHODOLOGY
OBJECTIVES
The primary objective of this study was to evaluate the impact of a practical, evidence-based
mental health treatment program integrated with HIV care, feasible for scale-up within the Malawi
health system, on mental health and HIV treatment outcomes. Specifically, among all patients
with mild, moderate, or severe depression, we aimed to evaluate the impact of the program on
the following primary HIV outcomes:
y Proportion of patients attending sufficient HIV appointments to maintain ART supply through the
first six months on ART (i.e., all monthly appointments through six months).
y Number of monthly HIV appointments attended in the first six months on ART.
y Proportion of patients with a HIV RNA viral load of <1,000 copies/mL approximately six months
after starting ART.
We further focused on the following secondary mental health outcomes:
y Proportion of patients with remission of depressive symptoms, defined as a PHQ-9 score <5, at
six months.
y Proportion of patients with a decrease of 50 percent or more in depressive symptoms from
baseline to six months.

STUDY DESIGN
This study employed a pre-post multiple baseline design to evaluate the impact of integrating
the depression treatment program within existing HIV clinical services on HIV and mental health
outcomes (Figure 1). Working in two public health clinics in urban Lilongwe, we launched a
Screening phase in both clinics in April and May 2017. The screening phase lasted 7 months
at Clinic A and 11 months at Clinic B. All patients starting ART and identified as having mild,
moderate, or severe depressive symptoms (PHQ-9 score ≥5) during the screening phase were
followed forward until six months after ART initiation for HIV appointment attendance, viral load,
and depressive symptom outcomes, even if this follow-up extended into the second (active)
phase.
At the conclusion of the screening phase, each clinic transitioned into the active phase. The
active phase lasted 12 months at Clinic A and six months at Clinic B. All patients starting ART and
identified as having mild, moderate, or severe depressive symptoms during the active phase were
followed forward until six months after ART initiation for the same outcomes listed above.
The screening and active phases are described in more detail in the next section.
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Figure 1 Study design

DESCRIPTION OF INTERVENTION
We integrated a depression screening and treatment program in two phases at two public HIV
clinics in Lilongwe, Malawi.
The first phase, known as the “screening“ phase, of the program launched in April 2017. During
this phase, we trained existing HIV post-test counselors and HIV providers to screen patients for
depression using the Patient Health Questionnaire-2 (PHQ-2) and, for those screening positive,
complete further assessment with the PHQ-9 to identify depressive symptom severity. ART
providers also received a refresher training on the existing care options for depression, typically
brief, single-session counseling by the ART provider, referral to off-site specialized psychiatric
services, or (rarely) prescription of amitriptyline. Amitriptyline was commonly available at both
clinics during the screening phase, as it is used to treat peripheral neuropathy, but providers had
limited familiarity with its use as an antidepressant and were most comfortable prescribing it at
doses for peripheral neuropathy that would be subtherapeutic for depression. Fluoxetine was not
available during the screening phase.
We also trained providers in assessment of and response to suicidal thoughts as indicated by any
response other than “Never“ on question 9 of the PHQ-9, which asks about any thoughts of being
better off dead or considering hurting oneself in the past two weeks. For patients endorsing any
such thoughts, providers were trained to complete a Suicide Risk Assessment form which guided
them through evaluating whether such thoughts were passive (thoughts of being better off dead)
or active (thoughts of actually hurting oneself), and the degree of severity of these thoughts or
behaviors. Providers were trained in the appropriate response depending on the level of severity
of the thoughts, ranging from brief safety assessment to immediate transport to the outpatient
psychiatric department at a nearby hospital.
In the second phase, known as the “active“ phase, ART providers were trained to provide
algorithm-based care for depression (ABCD). ABCD directs providers to refer patients with mild
depression for a problem-solving therapy intervention, while patients with moderate to severe
depression are initiated on antidepressants using an algorithm known as Measurement Based
Care (MBC). The problem-solving therapy intervention received by patients with mild depression
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was the evidence-based psychosocial counseling strategy originally developed in Zimbabwe
(The Friendship Bench) (Chibanda et al. 2011). The Friendship Bench tailored for the Malawi
setting was intended to be six 30- to 45-minute sessions over six weeks and was delivered by
clinic-based lay health workers, known as Health Surveillance Assistants (HSAs). There was no
expectation that patients would necessarily see the same counselor from one session to the next,
although patients and counselors could try to arrange for continuity if possible; staff availability
was the primary driver of which counselor was seen at the patient’s next return visit.
MBC directs providers to prescribe antidepressants (either fluoxetine or amitriptyline) and titrate
the dose accordingly based on antidepressant side effects and depression symptom severity
(PHQ-9 score) to patients with moderate to severe depression. ART providers re-administer the
PHQ-9 to patients at their monthly ART visits to monitor their depressive symptoms and manage
their treatment accordingly.

DATA COLLECTION METHODS
During both the screening and active phases, research assistants approached patients newly
initiating ART and invited them to participate in the program evaluation. Consenting patients
allowed the abstraction of their clinical data. To evaluate the impact of the program on HIV and
mental health outcomes, we abstracted mental health and HIV data from consenting patients’
clinical records from ART initiation up to a total of 13 months in care. Data included HIV
appointment attendance, ART medication dispensed, HIV viral load results, depression treatment
information (counseling sessions and antidepressants prescribed), and follow-up depressive
symptom assessments.
Patients with depressive symptoms received care according to the current phase (screening or
active) regardless of whether or not they provided consent for their data to be abstracted.

Box 1 Screening phase vs active phase explained
Screening phase
Depression screening

Depression treatment
No or minimal depression
Mild depression
Moderate to severe
depression

Active Phase

Integrated into HTC (PHQ-2 administered by counselors) and ART
initiation (PHQ-9 completed by ART clinicians or nurses)
Standard care

Algorithm-based care for
depression

None

None

Potential to include additional
counseling during ART, amitriptyline
prescription (typically at subtherapeutic dose), or referral to
mental health specialists

Friendship Bench counseling
provided by trained HSAs
Measurement Based Care
prescription of antidepressants
(amitriptyline or fluoxetine) by
ART clinicians or nurses
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ETHICAL REVIEW
The protocol was approved by the National Health Sciences Research Committee of Malawi
(NHSRC) and the Biomedical Institutional Review Board (IRB) of the University of North Carolina
at Chapel Hill. All research activities adhered to Malawian and US ethical standards for research
in human subjects. To ensure protection of patients’ identities and confidentiality, the study only
used routinely collected, de-identified clinical data to evaluate this treatment program.

DATA ANALYSIS
We begin by comparing the characteristics of those enrolled in the screening vs. active phases
to evaluate comparability of the two populations. We continue with descriptive information
about depression screening, treatment initiation, and treatment continuation, as well as on HIV
appointment attendance over the first six months on ART. We then compare the primary and
secondary outcomes between the screening and active phases.
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KEY FINDINGS
FEASIBILITY OF DEPRESSION SCREENING INTEGRATION
Between April 2017 and November 2018, 2,414 patients newly initiated ART at the two study
sites. Approximately 86 percent (n=2,067) of patients who newly initiated ART during this period
consented to allow the abstraction of their clinical data to evaluate the program. Nearly all
of consenting individuals (n=2,063) were screened with the PHQ-2, and 96 percent of those
screened with the PHQ-2 successfully completed depression screening. A quarter of the new ART
initiators reported mild (19%), moderate (6%), or severe (<1%) depressive symptoms (Figure 2).
Figure 2 Evaluation enrollment
New ART patients: 2,414

Consented: 2,067 (86%)

Missed: 4

Screened with PHQ-2: 2,063 (>99%)

Missed: 79

Screened with PHQ-9: 1,984 (96%)

PHQ-9 score 0–4:
1,483 (75%)

PHQ-9 score 5–9:
370 (19%)

PHQ-9 score 10–19:
1,483 (75%)

PHQ-9 score 20–27:
5 (<1%)

CHARACTERISTICS OF CONSENTING PARTICIPANTS
We enrolled 2,067 individuals in our program evaluation; 1,131 initiated during the screening
phase and 936 initiated during the active phase (Table 2). Just under half of participants were
male (47%). The mean age of participants (33.8) did not vary appreciably between the screening
and active phases. According to the World Health Organization’s (WHO) HIV clinical stages for
HIV surveillance (WHO 2005), nearly everyone (N=2,064) was classified as asymptomatic (Stage
1). Overall, 43 percent of participants scored above 0 on the PHQ-2, 19 percent reported mild
depression (PHQ-9 score 5–9), and 7 percent reported moderate to severe depression (PHQ-9
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score ≥10). The prevalence of suicidality was approximately 5 percent, with most being passive
suicidal ideation. There were no notable differences by sex.
Table 2 Characteristics of consenting patients
Overall
n (%) or mean (sd)

Screening phase
n (%) or mean (sd)

Active phase
n (%) or mean (sd)

2,067

1,131

936

Clinic A

1,143 (55%)

460 (41%)

683 (73%)

Clinic B

924 (45%)

671 (59%)

253 (27%)

Overall
Clinic

Sex
Male

980 (47%)

530 (47%)

450 (48%)

1,087 (53%)

601 (53%)

486 (52%)

33.8 (9.3)

33.5 (9.6)

34.2 (8.9)

2,062 (100%)

1,129 (100%)

933 (100%)

5 (0%)

2 (0%)

3 (0%)

1,134 (57%)

602 (55%)

532 (60%)

Minimal symptoms (PHQ-9 score 1–4)

349 (18%)

199 (18%)

150 (17%)

Mild symptoms (PHQ-9 score 5–9)

370 (19%)

214 (20%)

156 (17%)

Moderate symptoms (PHQ-9 score 10–19)

126 (6%)

71 (6%)

55 (6%)

5 (0%)

5 (0%)

0 (0%)

83

40

43

1,876 (95%)

1,026 (94%)

850 (95%)

Passive thoughts

56 (3%)

35 (3%)

21 (2%)

Active thoughts

46 (2%)

27 (2%)

19 (2%)

Not assessed

6 (0%)

3 (0%)

3 (0%)

Female
Age
WHO stage
I
II–IV
Depressive symptom severity
Screen-negative (PHQ-2 score = 0)

Severe symptoms (PHQ-9 score 20–27)
Not assessed
Suicidal thoughts
No thoughts

FEASIBILITY OF INITIATING DEPRESSION TREATMENT
During the screening phase, the majority of patients both with mild and moderate to severe
depression received brief counseling from their HIV clinician. During the active phase, 86 percent
of participants with mild depressive symptoms started Friendship Bench counseling and 96
percent of participant with moderate to severe depressive symptoms started an antidepressant
(Table 3). Treatment initiation indicators were comparable between the two clinics in the active
phase.
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Table 3 Baseline depression treatment plan
Screening Phase
n (%)

Active Phase
n (%)

214 (100%)

156 (100%)

191 (89%)

15 (10%)

Counseling by Friendship Bench (FB) counselor

0 (0%)

134 (86%)

Antidepressant (AD)

1 (0%)

0 (0%)

AD & clinician counseling

1 (0%)

0 (0%)

Mild depressive symptoms (PHQ-9 score 5–9)*
Counseling by HIV clinician

AD & FB counseling

0 (0%)

2 (1%)

21 (10%)

5 (3%)

76 (100%)

55 (100%)

Counseling by HIV clinician

60 (79%)

2 (4%)

Counseling by FB counselor

0 (0%)

0 (0%)

AD

7 (9%)

41 (75%)

AD & clinician counseling

7 (9%)

8 (15%)

AD & FB counseling

0 (0%)

4 (7%)

None

2 (3%)

0 (0%)

None*
Moderate to severe depressive symptoms (PHQ-9 score ≥10)

*Those with missing baseline treatment plan (n=4) treated as none; AD=antidepressants, FB=Friendship Bench

CONSISTENCY OF HIV APPOINTMENT ATTENDANCE
After ART initiation, about three quarters of participants in both phases returned for their 1-month
ART appointment whereas about one-quarter did not (28% and 25% during the screening and
active phase, respectively) (Figures 3 & 4). Attendance continued to decline thereafter. By the
6-month appointment window, only 36 percent and 35 percent attended an appointment during
the screening and active phase, respectively; another 10 percent (screening phase) and 6
percent (active phase) had been given a 60- or 90-day supply of ART at an earlier appointment
and were not expected to attend at six months. A small number of patients were known to have
died or transferred care, but a much larger proportion missed an appointment or were lost to
care (defined as having gone at least 30 days without ART, i.e., the prior scheduled appointment
was missed and the patient had gone at least 30 more days beyond the expected date of running
out of ART without an attended appointment). These follow-up rates are fairly comparable to
the clinic’s overall retention rate, with about 44 percent of all patients during this period either
attending an appointment or having an extended supply of ART (prior 60- or 90-day dispensed
supply) at six months. There were no notable differences by sex.
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Figure 3 Screening phase: HIV appointment attendance during first 6 months on ART
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Transferred out

Died

*Month 1=Days 1-45; Month 2=Days 46-76; Month 3=Days 77-106; Month 4=107-137; Month 5=138-167; Month 6=Days
168-197
**Patient has gone at least 30 days without ART, i.e., the prior scheduled appointment was missed and the patient had gone at
least 30 more days beyond the expected date of running out of ART without an attended appointment

Figure 4 Active phase: HIV appointment attendance during first 6 months on ART
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*Month 1=Days 1-45; Month 2=Days 46-76; Month 3=Days 77-106; Month 4=107-137; Month 5=138-167; Month 6=Days
168-197
**Patient has gone at least 30 days without ART, i.e., the prior scheduled appointment was missed and the patient had gone at
least 30 more days beyond the expected date of running out of ART without an attended appointment
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FEASIBILITY OF SUSTAINING DEPRESSION TREATMENT
An adequate course of depression treatment consists of six Friendship Bench counseling
sessions or at least three months of continuous antidepressant prescription with dosage
adjustments if indicated. Few patients received an adequate course of treatment, in part due
to the low overall HIV care retention rate and in part due to patients who attended clinic not
receiving follow-up depression care; the majority of inadequate depression treatment was due to
patients not returning to clinic, but a large proportion was also due to returning patients not being
identified for follow-up care (Appendix figures 5 and 6). During the active phase, only around onethird of individuals who were directed to receive Friendship Bench counseling completed four
or more sessions in their first six months of care (Table 4). In addition, only 18 percent (n=10)
of participants who were prescribed antidepressants at ART initiation received antidepressants
at four or more sessions over their first six months of care. Of these five individuals, only two
received four consecutive months of antidepressant prescriptions.
Table 4 Provision of depression treatment over first 6 months on ART
Active phase
overall

Active phase

Of those directed to FB counseling*

140 (100%)

Clinic A
107 (100%)

Number of FB sessions attended
1
2
3

60 (43%)
21 (15%)
13 (9%)

31 (29%)
19 (18%)
12 (11%)

29 (88%)
2 (6%)
1 (3%)

46 (33%)
55 (100%)

45 (42%)
44 (100%)

1 (3%)
11 (100%)

23 (42%)
15 (27%)
7 (13%)

14 (32%)
13 (30%)
7 (16%)

9 (82%)
2 (18%)
0 (0%)

10 (18%)

10 (23%)

0 (0%)

≥4
Of those prescribed AD**
Number of months of AD provided
1
2
3
≥4

Clinic B
33 (100%)

FB=Friendship Bench; AD=Antidepressants

PROGRAM IMPACT ON HIV AND DEPRESSION OUTCOMES
The primary outcome of this evaluation was HIV clinical success. HIV clinical success was
defined as meeting both of the following criteria: never more than two weeks late to a scheduled
appointment in the first six months of care and a viral load <1,000 copies/mL at the viral load
assessment conducted at approximately six months post-ART initiation. Overall, only one-quarter
of patients achieved HIV clinical success; 28 percent of patients from the screening phase and
22 percent of patients in the active phase (Table 5). There were no notable differences by sex.
Approximately one-third of patients from both the screening and active phases were retained
through six months (never more than two weeks late to a scheduled appointment in the first six
months). Nearly every patient with a measured viral load demonstrated viral suppression at six
months (94% and 91% in screening and active phase, respectively). Similarly, nearly every patient
with a 6-month PHQ-9 score achieved depression remission (94% and 97% in the screening and
active phases, respectively). The HIV and depression outcomes did not vary appreciably between
phases.
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Table 5 Program impact on HIV and depression outcomes among patients with mild, moderate,
or severe depression at baseline
Overall
(n=502)
n (%)

Screening
Phase
(n=291)
n (%)

Active Phase
(n=211)
n (%)

PRIMARY OUTCOME
HIV clinical success: Never >14 days late to an appointment
through 6 months and virally suppressed at 6 months
Yes

102 (25%)

68 (28%)

34 (22%)

No

301 (75%)

178 (72%)

123 (78%)

49

20

29

49

24

25

Retained, but missing viral load
Transferred out
SECONDARY OUTCOMES
Retained through 6 months: Never >14 days late to an
appointment
Yes

157 (35%)

91 (34%)

66 (35%)

No

295 (67%)

175 (66%)

120 (65%)

49

24

25

Transferred out
Currently on ART: Attended an appointment prior to 6 months with
a next appointment date after 6 months
Yes

225 (50%)

138 (52%)

87 (46%)

No

227 (50%)

128 (48%)

99 (54%)

49

24

25

0.57 (0.39)

0.57 (0.39)

0.59 (0.38)

Yes

185 (41%)

112 (42%)

73 (39%)

No

267 (59%)

154 (58%)

113 (61%)

49

24

25

0.68 (0.36)

0.69 (0.35)

0.67 (0.37)

Yes

168 (93%)

108 (94%)

60 (91%)

No

13 (7%)

7 (6%)

6 (9%)

Transferred
Proportion of scheduled HIV appointments attended within 1 week
[Mean (SD)]
Consistent ART supply through 6 months: Never >5 days without
ART

Transferred out
ART pill possession ratio* [Mean (SD)]
Virally suppressed at 6 months**

Retained, but no VL drawn

74

39

35

No attended appointment between months 5.5 and 8

197

112

85

Transferred out

49

24

25

Yes

124 (95%)

87 (94%)

37 (97%)

No

Depression remission (PHQ-9 score <5) at 6 months
7 (5%)

6 (6%)

1 (3%)

Attended appointment but no PHQ-9 completed

110

51

59

No attended appointment between months 5.5 and 8

211

122

89

Transferred out
PHQ-9 score at 6 months** [Mean (SD)]

49

24

25

1.0 (2.4)

1.2 (2.7)

0.6 (1.4)

VL=Viral Load; SD=Standard Deviation
*Proportion of 6 months (183 days) with ART. Numerator is the cumulative number of pills dispensed through 6 months. Pills
dispensed at last visit before 6-month prorated to be equivalent to the number of days between that visit and day 183 in care.
** Take from the first viral load/PHQ-9 after at least 5.5 months in care
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DISCUSSION
The objective of this study was to integrate a practical, feasible depression treatment program
into routine, real-world HIV care in Malawi and evaluate the impact of that integration on HIV and
mental health outcomes for patients newly initiating ART. The program was highly successful in
effectively integrating depression screening, assessment, and treatment initiation using existing
staff, but faced greater challenges in ensuring continuity of depression care at follow-up visits.
Generally, loss to HIV care was very high both before and after the program implementation,
but those patients retained in HIV care almost universally demonstrated viral suppression and
depression remission. There was no evidence of greater improvement in HIV or mental health
outcomes under the integrated program compared to the pre-implementation screening phase.
We were able to successfully integrate depression screening and treatment initiation into
starting HIV care. Over the course of this program, nearly all new ART initiators were screened for
depression with the PHQ-2, and 92 percent of patients with positive PHQ-2 screens completed the
PHQ-9. About one-quarter of study participants had mild to severe depression at ART initiation.
While a high percentage of participants started the appropriate depression treatment during the
active phase, few patients continued to receive counseling or antidepressants over their first six
months of care.
We attribute the success in integration of depression screening and treatment initiation to several
factors. First, we found that effectively utilizing existing ART initiation processes and infrastructure
was key (Udedi et al. 2018). For example, after careful study of the clinic flow, the additional work
and time burden of screening patients and initiating treatment was split across the HIV post-test
counselors and HIV providers. Additionally, we invested heavily in creating multiple opportunities
for iterative and collaborative learning (Udedi et al. 2018). We ensured that every HIV provider
received training in how to administer and interpret the PHQ-9, provide depression treatment, and
manage depressive symptoms over time.
However, sustaining depression management was challenging for the health care facilities. This
was in part due to structural challenges. At these clinics, providers typically use an electronic
medical record (EMR) system to manage ART care, with a parallel paper system populated with
barcodes from the EMR. As resources were lacking to build a depression module into the ART
EMR, we modified the paper recordkeeping system to track both ART and depression indicators.
Nevertheless, providers struggled to re-identify depressed patients returning for care so as to
provide appropriate follow-up. While the program team and the clinic staff worked together to
engineer a solution for this challenge by marking patients’ health passports, ultimately it was
difficult to overcome.
Furthermore, antidepressant stock-outs were common. Ostensibly, Malawi’s Essential Health
Package guarantees the availability of fluoxetine and amitriptyline free of charge for patients at
public clinics in Malawi (Government of Malawi Ministry of Health 2013). However, in practice
ensuring their availability at the clinic proved complicated, requiring substantial coordination
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between the providers, the clinic pharmacies, the clinic leadership, the district health officer, the
district health office pharmacy, and the national level medication reserves, often facilitated by
project staff. Other countries in the region such as Mozambique also have an essential drug list
that includes amitriptyline and fluoxetine; however, a recent study found that these drugs were
not frequently available at the district or clinic level (Wagenaar et al. 2015).
The clinics also faced some difficulties ensuring provision of Friendship Bench counseling with
existing staff. While the study did hire one dedicated Friendship Bench counselor at each clinic,
these study counselors were meant to provide back-up for the larger group of MOH-employed
community health workers trained as counselors. However, the study-employed counselors
ultimately provided the majority of the counseling at both sites, as the community health workers
had a very high workload and often traveled off-site to run various Ministry of Health initiatives.
Furthermore, while the original Friendship Bench protocol called for six weeks of weekly
Friendship Bench counseling sessions, nearly all patients were unable or unwilling to make extra
trips to the clinic for counseling sessions without compensation due to time and transportation
costs. As a result, nearly all of the Friendship Bench counseling sessions were provided monthly,
on the same day at the ART appointment, which may have impacted the effectiveness of the
counseling protocol. Future efforts to implement counseling protocols such as the Friendship
Bench should consider carefully (1) the capacity of the cadre designated to provide the
counseling and (2) how to support patients in regular attendance at sessions, for example with
transportation assistance or possibly community-based delivery of counseling.
This population proved a very challenging group to keep engaged in treatment. We observed
very high rates of loss to HIV care at both clinics, with only about one-quarter of participants
remaining consistently in care for the first six months and having a suppressed viral load. Even
when considering a somewhat more lenient definition of having ART at six months, fully half
of patients did not meet this definition. However, of those attending appointments and with
viral loads drawn around six months, nearly all were virally suppressed in both phases. These
and several other secondary measures of HIV care engagement showed no notable difference
between the screening and active phases. There are several possible explanations for this result.
First, those patients identified with depressive symptoms at ART initiation may have had a timelimited reactive depression or adjustment disorder rather than major depressive disorder, which
may have resolved independently of treatment in both phases. Indeed, depression remission
was extremely high among those who stayed in care and had a completed PHQ-9 around six
months—both among those with mild and those with moderate to severe depression at baseline.
Second, for patients with no prior exposure to any sort of mental health care, even the very basic
clinician-delivered counseling provided during the screening phase may have led to depression
improvements, reducing the difference between the two arms. Ethically, it was not possible to
have a pure “usual care“ phase where patients were screened and identified with depression
but no information was provided to clinicians and no clinical follow-up was permitted. Third,
depressive symptoms may have improved for all patients with the initiation of antiretroviral
therapy and the subsequent improvement in physical health. Indeed, several studies have found
such improvements among ART initiators in Africa (Okeke and Wagner 2013, Wagner et al. 2012).
This improvement may have masked the added benefit of the depression treatment program
in this population. Finally, although uptake of depression screening and depression treatment
initiation were high, achieving sustained depression treatment for multiple months proved
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challenging in this real-world context, which may also have limited the difference between the
screening and active phases.

LIMITATIONS
Our results should be carefully considered in light of several limitations. First, since the
primary outcome of the study was retention in HIV care, the study team intentionally did not
schedule research follow-up interviews, especially for the 6-month outcome, that could have
had the unintended effect of bringing participants back to clinic during the first six months and
influencing the primary outcome. Therefore. the extent of participants without 6-month viral
load and depression measures was greater than it would have been had the research team
scheduled follow-ups with participants. If those who did not remain in care were more likely to
have persistent depressive symptoms, the rate of depression remission reported here would be
an overestimate. Further, PHQ-9s at 6-month follow-up were administered by clinicians as part of
routine care. It is possible that part of the reduction in PHQ-9 scores observed between baseline
and six months reflected less careful administration by clinicians at the later time point.
The primary objective of the study was to estimate the impact of the depression treatment
program on HIV outcomes among the full patient population at the clinic. Since the primary
outcome could be assessed purely relying on medical chart data, the team decided not to include
a baseline patient interview that would have limited enrollment to those willing to spend the
additional time for the interview. As a result, very limited information is available on potential
confounders. However, the multiple baseline design should have protected against confounding
by producing balanced characteristics of patients in the screening and active phases; indeed, all
measured characteristics were very similar between the two phases.
Causal inference from this study relies on the validity of the multiple baseline design and
specifically the comparability of the patient population at each clinic during the screening and
active phases (or lack of confounding). As noted above, lack of confounding is supported by the
comparable distributions of measured characteristics between the screening and active phases.
Although the primary outcome used for this study (attending sufficient HIV appointments to
maintain ART supply through six months and having a suppressed viral load at six months) is
more stringent than the standard PEPFAR definition of retention in care, we saw similar results
with several different definitions of HIV care engagement, including the standard PEPFAR
measure (Table 5).
Finally, the primary outcome of retention in HIV care may have been influenced by “silent
transfers,“ or patients who switched care to another ART clinic without formally transferring their
records. Patients who requested record transfers were recorded as transfers, but any patients
who transferred silently would have been potentially misclassified as being out of care. However,
there is no reason to believe that the rate of silent transfers would have varied between the
screening and active phases, and therefore this potential measurement error should not have
introduced bias into the primary analyses.
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CONCLUSION AND
RECOMMENDATIONS
CONCLUSIONS
The SOAR-Malawi Mental Health Project demonstrated that it is feasible to integrate universal
depression screening and evidence-based antidepressant management and problem-solving
therapy counseling into routine care using existing staff in low-resource ART clinics in Malawi.
Although there was some initial resistance from clinicians to added work with no added pay, with
persistence and involvement of clinic leadership the program was successful in achieving over 90
percent coverage of depression screening and over 90 percent initiation of depression treatment
among those identified with elevated depressive symptoms over an 18-month period.
Although clinicians and staff received no extra pay or incentives, this success was not resourcefree. Beyond the one-time costs for training, success hinged on significant legwork and
“championing“ by the study coordinator. Further, the training of existing Health Surveillance
Assistants (clinic-based lay health workers) as problem-solving therapy counselors was not
effective. Despite multiple efforts to organize rosters and ensure a shared workload, the existing
HSAs were routinely pulled into other duties and not available for counseling. As a result, the
study-funded counselor at each clinic did the vast majority of counseling sessions.
Different challenges were raised by integration of antidepressants and counseling. After a oneday training, clinicians were comfortable initiating antidepressants and did so systematically with
very little increased time cost. However, because of challenging medical record systems, returning
patients on antidepressants were inconsistently identified and often did not have their depressive
symptom level re-assessed or receive a refill of their antidepressant. Further, although both
amitriptyline and fluoxetine are on the government essential medications list, stockouts did occur,
leading to medications being either discontinued or switched to the available antidepressant
for some patients. In addition, although regular supervision is a critical aspect of supporting
non-specialists in delivering depression care, very few clinicians attended the biweekly clinical
supervisions held by the study team (for which no allowance was offered), even after multiple
interventions with clinic and district leadership.
Counseling, on the other hand, was not affected by stockouts or medical record challenges since
patients knew where to find the counselor. However, counseling was significantly more timeintensive, and integration into the workload of existing staff proved infeasible. Further, follow-up
for counseling was poor. Patients, facing time and transportation costs, proved unable or unwilling
to come to more frequent counseling sessions without travel reimbursement. As a result,
counseling sessions occurred monthly at ART appointments rather than weekly as recommended,
and few patients ended up receiving the recommended six sessions.
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Retention in HIV care through the first six months on ART was poor at our two clinics in both
the screening and active phases. Among those who did remain in care, viral suppression and
depression remission at six months were both very high. We saw no evidence of improved
HIV care or mental health outcomes with the depression treatment program relative to the
screening phase. This may have been because most depression at ART initiation was time-limited
adjustment disorder, because even the basic one-time counseling provided during the screening
phase was impactful, or because ART initiation and subsequent physical health improvement led
to mental health improvement in both phases.

RECOMMENDATIONS
Several key recommendations arise from the SOAR-Malawi Mental Health Project.
First, efforts to integrate depression screening and treatment within routine ART care in resourcelimited settings are definitely feasible, but will greatly benefit from the following:
y A dedicated, funded on-site champion.
y Integration with electronic medical record systems where feasible (many clinics in Malawi use
the Baobab Health electronic system for ART records), which would ensure that screening is
completed and returning patients on antidepressant treatment are identified and re-assessed.
y Dedicated counseling personnel (other research has demonstrated that community members,
who may be willing to commit for a small stipend, can be trained and supervised to effectively
deliver problem-solving therapy).
y Identification of appropriate and sustainable incentives (monetary or non-monetary) that will
ensure that clinicians participate in clinical supervision sessions to maintain and enhance
these new skills.
y Identification of appropriate and sustainable means of support to encourage patients to
complete the recommended weekly counseling sessions.
Second, this program did not find evidence that HIV care or mental health outcomes improved
during the treatment program relative to the screening phase. While this program focused on
patients newly initiating ART as a population at high risk for loss to care, depression treatment
may be more important for returning patients who may present with more persistent or severe
depressive symptoms and face challenges in maintaining long-term ART adherence and HIV care
engagement.
Third, efforts to integrate depression care into HIV clinical services may need to consider the
evolving ART delivery landscape, with increasing emphasis on reducing clinical appointments by
providing multiple months’ ART supply and expanding community ART delivery. Integration efforts
may need to be creative about where and when to engage patients in depression screening and
care, and potentially consider different follow-up schedules for patients on stable ART without
complications vs. patients who require more frequent follow-up for management of comorbidities
such as mental health.
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APPENDICES
PHQ-9 SCREENING
The Patient Health Questionnaire-9 (PHQ-9) is a widely used nine item instrument that assesses
the presence of nine symptoms of depression within the previous two weeks as specified by
the Diagnostic and Statistical Manual of Mental Disorders IV (American Psychiatric Association
2000). Each of the nine items is scored from 0 (not at all) to 3 (nearly every day). The first two
questions—known as the Patient Health Questionnaire-2 (PHQ-2)—capture depressed mood and
anhedonia, the two core symptoms of depression. A total score of 5–9, 10–14, 15–19, or 20
and above are considered indicative of mild, moderate, moderately severe, or severe depression,
respectively (Kroenke, Spitzer and Williams 2001).
The HIV testing and counseling (HTC) providers screened patients with the PHQ-2 after a positive
test for HIV. ART providers then screened patients who scored above 0 on the PHQ-2 with the
remaining seven questions of the PHQ-9, assessing for the presence of the remaining seven
symptoms of depression. ART providers then used the PHQ-9 to reassess patients for depression
at their subsequent ART follow-up visits.
The PHQ-9 is one of a number of mental health screening tools that have been used in Malawi
and other African countries. It was chosen because it focuses specifically on depression, has
been widely used and validated in many different settings (Gelaye et al. 2013), and works well
both as a screening tool for depression as well as a longitudinal measure to monitor response
to treatment. This tool had been validated for use in HIV-positive populations in other countries
in the region (Cholera et al. 2014, Monahan et al. 2009) and had been used in one other study
in Malawi (Malava et al. 2018). It has since been validated among a population of people
living with diabetes. The standard PHQ-9 was augmented with an additional screening protocol
to probe the degree of severity of suicidality in patients who screened positive for suicidal
ideation on the PHQ-9. Both the PHQ-9 and associated suicide risk assessment protocol were
translated into Chichewa, the vernacular language in the central region of Malawi. This entailed
an iterative process involving the health workers to ensure that the PHQ-9 adequately captures
the depressive symptoms yet is culturally understandable. The translated instrument is currently
being validated.
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PHQ-9

PHQ-2

Patient Health Questionnaire-9
1. During the past two weeks, how many days have
you been bothered by feeling down, depressed, or
hopeless?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

2. During the past two weeks, how many days have
you been bothered by little interest or pleasure in
doing things?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

3. During the past two weeks, how many days have
you been bothered by trouble falling or staying asleep,
or sleeping too much?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

4. During the past two weeks, how many days have
you been bothered by feeling tired, fatigued or having
little energy?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

5. During the past two weeks, how many days have
you been bothered by poor appetite or overeating?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

6. During the past two weeks, how many days have
you been bothered by feeling bad about yourself—or
that you are a failure or have let yourself or your family
down?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

7. During the past two weeks, how many days have
you been bothered by trouble concentrating on things,
such as reading, talking with friends, finishing tasks,
or attending a meeting?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

8. During the past two weeks, how many days
have you been bothered by moving or speaking so
slowly that other people could have noticed? Or the
opposite—being so fidgety or restless that you have
been moving around a lot more than usual?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

9. During the past two weeks, how many days have
you been bothered by thoughts that you would be
better off dead or of hurting yourself in some way?

0 days
(0)

1–7 days
(1)

8–12 days
(2)

13 or 14 days
(3)

FRIENDSHIP BENCH
The Friendship Bench therapy is an adapted form of problem-solving therapy that was developed
over many years of formative research in Zimbabwe (Abas et al. 2016, Chibanda et al. 2011,
Chibanda et al. 2016, Pierce 2012). Friendship Bench therapy consists of patient-centered
counseling that teaches patients how to identify triggers and effectively manage stressful life
events by learning or reactivating problem-solving skills. Specifically, counselors guide patients
through recognizing problems, identifying their own solutions, implementing those solutions,
and assessing the outcome (Chibanda et al. 2011, Pierce 2012). The original Friendship Bench
was designed to be delivered by lay health care workers and called for patients to receive six
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weekly counseling sessions. However, in line with the patient-centered approach, patients were
encouraged to set their own return dates.
During the active intervention phase of the program, ART providers were trained to refer
participants with mild depressive symptoms (PHQ-9 score 5–9) to clinic-based lay health workers,
called HSAs, or a project-employed counselor trained to provide Friendship Bench Therapy. The
first session would often last about 45 minutes to an hour and subsequent sessions would
be shorter (around 15 to 30 minutes). Patients referred to the Friendship Bench would ideally
receive at least six counseling sessions over their first six months in care. Again, patients were
encouraged to return weekly for Friendship Bench therapy, but ultimately patients set their own
appointments in line with the protocol’s patient-centered approach. The program built covered
shelters with seating areas at both clinics to serve as the Friendship Bench in an effort ensure
there would be a dedicated space for the Friendship Bench counselors to work.

MEASUREMENT BASED CARE
Measurement Based Care (MBC) is a resource-efficient, task-sharing model for prescribing
antidepressant management in non-psychiatric settings. This model of care has demonstrated
safety, feasibility, and acceptability when adapted for HIV care and delivered by general practice
medical providers in Cameroon, Tanzania, and Uganda (Adams et al. 2012a, Pence et al. 2014,
Wagner et al. 2016). The model of care uses PHQ-9 scores to monitor depressive symptoms
in combination with an assessment of side effects and antidepressant tolerability to guide
antidepressant prescription.
During the active intervention phase, ART providers prescribed antidepressants to patients with
moderate to severe depression (PHQ-9 ≥ 10). At the subsequent follow-up visits, ART providers
would reassess patients’ depressive symptoms with the PHQ-9 and assess the medication’s
tolerability. Providers would use changes in depressive symptoms and medication tolerability to
guide management of patients’ antidepressant prescription, with options to increase or decrease
the dose or change the type of antidepressant prescribed.
Depression screening coverage, by clinic and period
Initiating
ART
N

Completing
PHQ-2
n (%)

With PHQ-2
score >0
n (%)

Completing
PHQ-9
n (%)

With PHQ-9
score ≥5
n (%)

Overall
prevalence of
any depressive
symptoms
n (%)

Overall

2,414

2,216 (92%)

952 (43%)

862 (91%)

502 (58%)

502 (24%)

Clinic A

1,370

1,259 (92%)

557 (44%)

487 (87%)

276 (57%)

276 (23%)

Clinic B

1,044

957 (92%)

395 (41%)

375 (95%)

226 (60%)

226 (24%)

Screening phase

1,308

1,182 (90%)

533 (45%)

488 (92%)

287 (59%)

287 (25%)

Active phase

11,06

1,034 (93%)

419 (41%)

374 (89%)

215 (57%)

215 (22%)

Patients:
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Study population, by clinic and period
Overall
n (%) or
mean (sd)

Screening
phase
n (%) or
mean (sd)

Active phase
n (%) or
mean (sd)

2,067

1131

Clinic A

1,143 (55%)

Clinic B

Screening phase

Active phase

Clinic A
n (%) or
mean (sd)

Clinic B
n (%) or
mean (sd)

Clinic A
n (%) or
mean (sd)

Clinic B
n (%) or
mean (sd)

936

460

671

683

253

460 (41%)

683 (73%)

460 (100%)

—

683 (100%)

—

924 (45%)

671 (59%)

253 (27%)

—

671 (100%)

—

253 (38%)

Screening

—

—

—

460 (100%) 671 (100%)

—

—

Active

—

—

—

—

—

683 (100%)

253 (38%)

980 (47%)

530 (47%)

450 (48%)

228 (50%)

302 (45%)

340 (50%)

110 (43%)

1,087 (53%)

601 (53%)

486 (52%)

232 (50%)

369 (55%)

343 (50%)

143 (57%)

33.8 (9.3)

33.5 (9.6)

34.2 (8.9)

33.9 (9.5)

33.1 (9.7)

34.7 (9.0)

32.9 (8.5)

2,062 (100%)

1,129 (100%)

933 (100%)

5 (0%)

2 (0%)

3 (0%)

2 (0%)

0 (0%)

3 (0%)

0 (0%)

Screen-negative
(PHQ-2 score = 0)

1,134 (55%)

602 (53%)

532 (57%)

237 (52%)

365 (54%)

361 (53%)

171 (68%)

Minimal symptoms
(PHQ-9 score 1–4)

349 (17%)

199 (17%)

150 (16%)

82 (18%)

118 (18%)

120 (18%)

30 (12%)

Mild symptoms
(PHQ-9 score 5–9)

370 (18%)

214 (17%)

156 (17%)

87 (19%)

128 (19%)

117 (17%)

39 (15%)

Moderate symptoms
(PHQ-9 score 10–19)

126 (6%)

71 (6%)

55 (6%)

28 (6%)

43 (6%)

43 (6%)

12 (5%)

Severe symptoms
(PHQ-9 score 20–27)

5 (0%)

5 (0%)

0 (0%)

1 (0%)

4 (1%)

(0%)

(0%)

83

40

43

25

15

42

1

1,876 (95%)

1,026 (94%)

850 (95%)

418 (96%)

608 (93%)

605 (94%)

245 (97%)

Passive thoughts

56 (3%)

35 (3%)

21 (2%)

9 (2%)

26 (4%)

18 (3%)

3 (1%)

Active thoughts

46 (2%)

27 (2%)

19 (2%)

7 (2%)

20 (3%)

18 (3%)

1 (0%)

Not assessed

6 (0%)

3 (0%)

3 (0%)

1 (0%)

2 (0%)

0 (0%)

3 (1%)

Overall [N]
Clinic

Phase

Sex
Male
Female
Age
WHO disease stage
I
II–IV

458 (100%) 671 (100%) 680 (100%) 253 (100%)

Depression screening
and severity status

Not assessed
Suicidal thoughts
No thoughts
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Baseline depression treatment plan, by clinic and period
Overall
n (%)

Screening
phase
n (%)

Clinician counseling

206 (56%)

191 (89%)

FB counseling

134 (36%)

0 (0%)

AD

1 (0%)

1 (0%)

AD & clinician
counseling

1 (0%)

Active phase
n (%)

Screening phase

Active phase

Clinic A
n (%)

Clinic B
n (%)

Clinic A
n (%)

Clinic B
n (%)

15 (10%)

77 (89%)

114 (90%)

11 (9%)

4 (10%)

134 (86%)

0 (0%)

0 (0%)

103 (88%)

31 (79%)

0 (0%)

0 (0%)

1 (1%)

0 (0%)

0 (0%)

1 (0%)

0 (0%)

0 (0%)

1 (1%)

0 (0%)

0 (0%)

Mild depressive
symptoms (PHQ-9
score 5-9)*

AD & FB counseling

2 (1%)

0 (0%)

2 (1%)

0 (0%)

0 (0%)

2 (2%)

0 (0%)

None*

26 (7%)

21 (10%)

5 (3%)

10 (11%)

11 (9%)

1 (1%)

4 (10%)

62 (47%)

60 (79%)

2 (4%)

18 (62%)

42 (89%)

1 (2%)

1 (8%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

AD

48 (37%)

7 (9%)

41 (75%)

5 (17%)

2 (4%)

37 (86%)

4 (33%)

AD & clinician
counseling

15 (11%)

7 (9%)

8 (15%)

5 (17%)

2 (4%)

3 (7%)

5 (42%)

AD & FB counseling

4 (3%)

0 (0%)

4 (7%)

0 (0%)

0 (0%)

2 (5%)

2 (17%)

None

2 (2%)

2 (3%)

0 (0%)

1 (3%)

1 (2%)

0 (0%)

0 (0%)

Moderate depressive
symptoms (PHQ-9
score ≥10)
Clinician counseling
FB counseling

*Those with missing baseline treatment plan (n=4) treated as none; AD=antidepressants, FB=Friendship Bench

Integrating depression management into HIV care in Lilongwe, Malawi: FeasIbility and impact ■ 29

Provision of depression treatment over first 6 months on ART during active phase
Window (Day since ART initiation)
0

1–45

46–76

77–106

107–137

138–167

168–197

130 (93%)

62 (44%)

50 (36%)

46 (33%)

31 (22%)

9 (6%)

11 (8%)

HIV appointment attended;
completed 6 FB sessions

0 (0%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

10 (7%)

12 (9%)

HIV appointment attended
but no FB session

10 (7%)

40 (29%)

44 (31%)

38 (27%)

36 (26%)

36 (26%)

29 (21%)

Did not come to clinic

0 (0%)

37 (26%)

43 (31%)

49 (35%)

60 (43%)

69 (49%)

70 (50%)

Transferred out

0 (0%)

1 (1%)

3 (2%)

7 (5%)

13 (9%)

16 (11%)

18 (13%)

55 (100%)

20 (36%)

10 (18%)

12 (22%)

13 (24%)

8 (15%)

4 (7%)

PHQ-9 assessed; no AD
provided

0 (0%)

5 (9%)

8 (15%)

6 (11%)

3 (5%)

1 (2%)

1 (2%)

No PHQ-9 assessed; no AD
provided

0 (0%)

18 (33%)

15 (27%)

15 (27%)

11 (20%)

13 (24%)

17 (31%)

Did not come to clinic

0 (0%)

11 (20%)

20 (36%)

20 (36%)

25 (45%)

29 (53%)

29 (53%)

Transferred out

0 (0%)

1 (2%)

2 (4%)

2 (4%)

3 (5%)

4 (7%)

4 (7%)

Of those directed to FB:
HIV appointment attended &
FB session attended

Of those prescribed
antidepressants:*
PHQ-9 assessed; AD
provided

*antidepressants include either AD and AD and FB; AD = antidepressants; FB = Friendship Bench
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49

Transferred out

49

Transferred out

ART pill possession ratio* [Mean (SD)]

25
0.67 (0.37)

24
069 (0.35)

49

73 (39%)

0.68 (0.36)

112 (42%)

114 (61%)

No

0.57 (0.4)

25

99 (56%)

87 (44%)

256

121 (65%)

6 (35%)

25

29

123 (78%)

34 (22%)

Active phase
n (%)

153 (58%)

185 (41%)
267 (59%)

Yes

Consistent ART supply through 6 months: Never >5 days
without ART

0.56 (0.4)

49

Proportion of scheduled HIV appointments attended within
one week [Mean (SD)]
0.57 (0.4)

24

227 (51%)

No

Transferred

128 (48%)

225 (49%)

Yes

Currently on ART: Attended an appointment prior to 6 months
with a next appointment date after 6 months
138 (52%)

24

296 (65%)

No

Transferred out

175 (66%)

157 (35%)

91 (34%)

24

20

178 (72%)

68 (28%)

Screening
phase
n (%)

Yes

Retained through 6 months: Never >14 days late to an
appointment

SECONDARY OUTCOMES

48

301 (75%)

No

Retained, but missing viral load

102 (25%)

Yes

HIV clinical success: Never >14 days late to an appointment
through 6 months and virally suppressed at 6 months

PRIMARY OUTCOME

Overall
n (%)

Program impact on HIV and depression outcomes, by clinic and period

0.8 (0.3)

18

47 (48%)

51 (52%)

0.62 (0.4)

18

40 (41%)

58 (59%)

18

56 (57%)

42 (43%)

18

5

58 (62%)

35 (38%)

0.8 (0.3)

6

106 (64%)

61 (36%)

0.52 (0.4)

6

88 (53%)

80 (47%)

6

119 (71%)

49 (29%)

6

15

120 (78%)

33 (22%)

Clinic B
n (%)

Screening phase
Clinic A
n (%)

0.8 (0.3)

19

84 (59%)

58 (41%)

0.59 (0.4)

19

73 (54%)

68 (46%)

19

86 (61%)

55 (39%)

19

22

89 (75%)

30 (25%)

0.7 (0.3)

6

30 (67%)

15 (33%)

0.53 (0.4)

6

26 (62%)

19 (38%)

6

34 (76%)

11 (24%)

6

7

34 (89%)

4 (11%)

Clinic B
n (%)

Active phase
Clinic A
n (%)
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49

Transferred out
1.2 (2.7)

24

122

51

6 (6%)

0.6 (1.4)

25

89

59

1 (3%)

37 (97%)

25

85

35

6 (9%)

60 (91%)

1.8 (3.2)

18

32

23

4 (9%)

39 (91%)

18

29

14

3 (5%)

52 (95%)

0.7 (2.0)

6

90

28

2 (4%)

48 (96%)

6

83

25

4 (7%)

56 (93%)

0.6 (1.4)

19

64

40

1 (3%)

36 (97%)

19

62

25

5 (9%)

49 (91%)

0 (0)

6

25

19

0 (0%)

1 (100%)

6

23

10

1 (8%)

11 (92%)

** # of patients for whom viral loads were drawn, but results are not yet available

*Proportion of 6 months (183 days) with ART. Numerator is the cumulative number of pills dispensed through 6 months. Pills dispensed at last visit before 6-month prorated to be equivalent
to the number of days between that visit and day 183 in care.

VL=Viral Load; SD=Standard Deviation

1 (2.4)

211

No attended appointment between months 5.5 and 8

PHQ-9 score at 6 months [Mean (SD)]

110

7 (5%)

No

Attended appointment but no PHQ-9 completed

124 (95%)

Yes

87 (94%)

24

49

Depression remission (PHQ-9 score <5) at 6 months

Transferred out

112

197

No attended appointment between months 6 and 8

39

7 (6%)

74

13 (7%)

No

108 (94%)

Retained, but no VL drawn

168 (93%)

Yes

Virally suppressed at 6 months**

Of those who were directed to receive Friendship Bench counseling, 93 percent started
Friendship Bench counseling the same day they initiated ART (Figure 5). During the first followup visit window (between days 1 and 45), only 44 percent of these patients also attended a
Friendship Bench session. By the 6-month window (between days 168 and 197), only 8 percent
of these patients also attend a Friendship Bench session and only 9 percent attended an ART
appointment and had attended six Friendship Bench sessions prior to the start of this window.
Over the course of the first six months of care, an increasing proportion of patients did not come
to the clinic; by the 6-month window half of patients did not attend an appointment.
Figure 5 Provision of depression treatment over first 6 months on ART during the active phase
among those directed to receive Friendship Bench counseling (N=140)
100%

80%

60%

40%

20%

0%

1–45

46–76

77–106

107–137

138–167

HIV appointment attended & FB session attended

Did not come to clinic

HIV appointment attended; completed 6 FB sessions

Transferred out

HIV appointment attended but no FB session

Died

168–197

FB=Friendship Bench

Of the patients prescribed antidepressants, one-third received a second prescription of
antidepressants at their first follow-up visit. By the 6-month window (between days 168 and
197), only 7 percent of patients attended an appointment and received antidepressants (Figure
6). During every follow-up window, between 20 percent and 33 percent of patients attended an
appointment, but were not reassessed with the PHQ-9 and thus did not receive antidepressants.
Similar to the patients who were referred for Friendship Bench counseling, patients who started
antidepressants increasingly did not come to the clinic; by the 6-month window over half of
patients did not attend an appointment.
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Figure 6 Provision of depression treatment over first 6 months on ART during the active phase
among those prescribed antidepressants (N=55)
100%

80%

60%

40%

20%

0%

1–45

46–76

77–106

107–137

138–167

PHQ-9 assessed; AD provided

Did not come to clinic

PHQ-9 assessed; no AD provided

Transferred out

No PHQ-9 assessed; no AD provided

Died

AD = antidepressants
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168–197
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